U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07303387) titled 'Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.' on Nov. 24.
Brief Summary: Rational, objective and design: Some cancer-protecting genes are inactivated when the EZH2 enzyme is too active or the SWI/SNF complex is less active. The EZH1/2 enzymes and the SWI/SNFs complex play opposing roles in gene expression: we hypothesize that valemetostat, an inhibitor of the EZH1/2 enzymes, will stop/slow down the growth of cancer cells by reactivating these genes. Numerous clinical trials are currently underway worldwide to optimize the development of valemetostat tosylate and potentially offer a new targeted the...